Literature DB >> 11707679

Higher efavirenz plasma levels correlate with development of insomnia.

M Núñez, D González de Requena, L Gallego, I Jiménez-Nácher, J González-Lahoz, V Soriano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11707679     DOI： 10.1097/00126334-200112010-00015

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  39 in total

1.  Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice.

Authors:  Niamh Higgins; Alice Tseng; Nancy L Sheehan; Charles J L la Porte
Journal:  Can J Hosp Pharm       Date:  2009-11

2.  Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

Authors:  Salvador Cabrera Figueroa; Alicia Iglesias Gómez; Almudena Sánchez Martín; María de la Paz Valverde Merino; Alfonso Domínguez-Gil Hurlé; Miguel Cordero Sánchez
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

Authors:  David Burger; Ilse van der Heiden; Charles la Porte; Marchina van der Ende; Paul Groeneveld; Clemens Richter; Peter Koopmans; Frank Kroon; Herman Sprenger; Jan Lindemans; Paul Schenk; Ron van Schaik
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

4.  Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.

Authors:  Chonlaphat Sukasem; Tim R Cressey; Pattamawan Prapaithong; Yardpiroon Tawon; Ekawat Pasomsub; Chutatip Srichunrusami; Thawinee Jantararoungtong; Marc Lallement; Wasun Chantratita
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

5.  Insomnia symptoms and HIV infection among participants in the Women's Interagency HIV Study.

Authors:  Girardin Jean-Louis; Kathleen M Weber; Bradley E Aouizerat; Alexandra M Levine; Pauline M Maki; Chenglong Liu; Kathryn M Anastos; Joel Milam; Keri N Althoff; Tracey E Wilson
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

6.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz
Journal:  Pharmacol Res       Date:  2016-05-06       Impact factor: 7.658

7.  Discordant genotypic resistance and HIV-1 genetic diversity from paired plasma and cerebrospinal fluid samples in Chinese settings.

Authors:  Lifeng Liu; Yulin Zhang; Feili Wei; Qingxia Zhao; Xicheng Wang; Lin Yuan; Ning Li; Dexi Chen
Journal:  J Neurovirol       Date:  2013-01-17       Impact factor: 2.643

8.  Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.

Authors:  Sofia A Pereira; Umbelina Caixas; Teresa Branco; Isabel Germano; Fátima Lampreia; Ana L Papoila; Emília C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2008-06-09       Impact factor: 4.335

Review 9.  The pharmacologic management of insomnia in patients with HIV.

Authors:  Toma S Omonuwa; Harold W Goforth; Xavier Preud'homme; Andrew D Krystal
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

10.  The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

Authors:  Samir K Gupta; Susan L Rosenkranz; Yoninah S Cramer; Susan L Koletar; Lynda A Szczech; Valerianna Amorosa; Stephen D Hall
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.